Drug Information
Drug Generic Name | CRISANTASPASE (Asparaginase) |
Drug Class | PROTEASOME INHIBITOR |
Chapter | Malignant Disease & Immunosuppression |
Asparaginase contains the enzyme L-asparagine amidohydrolase which hydrolyses serum asparagine to nonfunctional aspartic acid and ammonia, depriving tumour cells of a required amino acid. Indications: Acute lymphoblastic leukaemias (induction regimen in paediatric). Cautions: Intradermal skin test should be performed prior to initial administration of this drug and repeated when at least 1 week separates doses (to avoid risk of anaphylaxis); monitor frequently serum amylase to detect early evidence of pancreatitis. If pancreatitis occurs, discontinue therapy. Contra-indications: Anaphylactic reactions to asparaginase; pancreatitis or a history of pancreatitis; pregnancy & breast feeding. Side Effects: anaphylaxis, nausea, vomiting, pancreatitis, CNS depression, and liver and blood lipid changes. Careful monitoring is, therefore, necessary and the urine should be tested for glucose because of a risk of hyperglycaemia. |
|
Brand Name |
|